Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Mondobiotech Holding AG Basel (RLFTF) Message Board

$RLFTF (copy) From poster “LA” on Yahoo board:

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 653
(Total Views: 619)
Posted On: 01/27/2021 11:28:26 PM
Avatar
Posted By: mc67
$RLFTF (copy) From poster “LA” on Yahoo board:

“The part that I found the best in the sec filing was this:

The RCT’s Data Monitoring Committee released clinical results of the first 21 patients to OWS for unblinded review. At the request of OWS, these data have been combined with 21 aviptadil-treated patients and 24 concurrent standard of care controls.

A dramatic effect on both survival and recovery from respiratory failure was documented in the combined data set of 31 aviptadil-treated vs 35 control patients (Figure 5). Additionally, a 2.8-point difference in NIAID ordinal scale (P<0.0001) and a 112-point difference in PaO2:FiO2 blood oxygenation index (P<0.0001) difference was demonstrated.

All underlying data and SAS programming code were shared with OWS for detailed examination and verification.

The improvement in recovery from respiratory failure and in survival was preceded in many cases by clear radiographic improvement. In the 21 aviptadil-treated patients from the Houston Methodist study, clear bilateral improvement was noted in 17 patients and unilateral improvement was documented in 2 patients (Figure 5).


A laboratory panel of inflammatory markers, including LDH, troponin, C-reactive protein, ferritin, D-Dimer, and interleukin 6 was obtained prior to and post treatment with aviptadil. In all patients, improvement can be documented on each of the inflammatory markers.

The largest average percent decrease was measured in C-reactive protein (76% ±3%) and interleukin 6 (75% ±3%). No patient demonstrated an increase in any of the inflammatory markers. In contrast, no significant reduction was identified in mean laboratory values for control patients.


This means that 10 of the 21 trial patients that were treated were included with the 21 open label trial and 11 placebo including with the 24 SOC patients and both survival and recovery were documented with multiple clinical and lab endpoints showing p <0.0001.


Just amazing. Also makes me wonder why US didn’t move faster on using this knowing what they knew with 4k people dying a day.”


(1)
(0)




Mondobiotech Holding AG Basel (RLFTF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


$MJ




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us